Nextcure (NXTC) closed at $6.53 on October 29, 2026, up 2.9% from the previous close, on volume of 58,012 shares (30-day average 86,189).
Data as of October 29, 2026.
NextCure CMO Departs Amid Pending Avere Merger
TipRanks (Fri, 30-Oct 8:29 AM ET)
PRNewswire (Mon, 10-Aug 7:00 AM ET)
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
Globe Newswire (Thu, 6-Aug 4:01 PM ET)
NextCure Shareholders Face Just 1.21% Ownership in New Avere Merger—Is This a Fair Deal?
Market Chameleon (Mon, 27-Jul 7:24 AM ET)
Market Chameleon (Tue, 14-Jul 5:52 AM ET)
NextCure Raises $21.5 Million in Private Placement, Extends Cash Runway Into 2027
Market Chameleon (Wed, 12-Nov 3:49 AM ET)
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Nextcure trades on the NASDAQ stock market under the symbol NXTC.
As of October 30, 2026, NXTC stock price declined to $6.33 with 12,405 million shares trading.
NXTC has a beta of 3.52, meaning it tends to be more sensitive to market movements. NXTC has a correlation of 0.06 to the broad based SPY ETF.
NXTC has a market cap of $28.97 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, NXTC traded as high as $30.84 and as low as $1.55.
The top ETF exchange traded funds that NXTC belongs to (by Net Assets): VTI, VXF, IWC, DFMC, DFAC.
NXTC has underperformed the market in the last year with a price return of -47.1% while the SPY ETF gained +10.4%. However, in the short term, NXTC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +26.1% vs +3.2% return in SPY. But in the last 2 weeks, NXTC shares have been beat by the market, returning -8.0% compared to an SPY return of -2.7%.
NXTC support price is $5.89 and resistance is $7.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NXTC shares will trade within this expected range on the day.
